Herpetic keratitis. Proctor Lecture.
Although much needs to be learned about the serious clinical problem of herpes infection of the cornea, we have come a long way. We now have effective topical antiviral drugs. We have animal models which, with a high degree of reliability, clearly predict the effect to be expected clinically in man, as well as the toxicity. We have systemically active drugs and the potential of getting highly active, potent, completely selective drugs, with the possibility that perhaps the source of viral reinfection can be eradicated. The biology of recurrent herpes and stromal disease is gradually being understood, and this understanding may result in new and better therapy of this devastating clinical disease.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D001973:Bromodeoxyuridine / Q000627:therapeutic use; D055598:Chemical Phenomena; D002621:Chemistry; D003320:Corneal Ulcer / Q000188:drug therapy; D004279:DNA, Viral / Q000096:biosynthesis; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D006801:Humans; D007065:Idoxuridine / Q000494:pharmacology / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D007635:Keratitis, Dendritic / Q000188:drug therapy* / Q000473:pathology; D019384:Nucleic Acid Synthesis Inhibitors; D012008:Recurrence; D014271:Trifluridine / Q000627:therapeutic use; D014740:Vidarabine / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000998:Antiviral Agents; D004279:DNA, Viral; D019384:Nucleic Acid Synthesis Inhibitors; D007372:Interferons; D014740:Vidarabine; D001973:Bromodeoxyuridine; D007065:Idoxuridine; D014271:Trifluridine